The White House’s plan to begin offering booster shots next month to almost all vaccinated U.S. adults is raising concerns among health experts that the administration is rushing ahead without enough data and regulatory oversight.
On Wednesday as expected, officials from the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, along with the U.S. Surgeon General and White House Covid-19 adviser Anthony Fauci, announced the booster plan. But it came without the FDA and CDC publicly saying they had fully vetted giving a third shot to the 100 million fully-vaccinated Americans by year’s end.
Messenger RNA vaccines made by Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE will be used in the booster push, according to the announcement. Johnson & Johnson’s is still under review because it came into use later.
These vaccines were cleared under an emergency use authorization (EUA) that would have to be amended to allow the booster program to go forward.